CLONAPAM TABLET

Country: Կանադա

language: անգլերեն

source: Health Canada

buyitnow

SPC SPC (SPC)
01-09-2021

active_ingredient:

CLONAZEPAM

MAH:

BAUSCH HEALTH, CANADA INC.

ATC_code:

N03AE01

INN:

CLONAZEPAM

dosage:

0.5MG

pharmaceutical_form:

TABLET

composition:

CLONAZEPAM 0.5MG

administration_route:

ORAL

units_in_package:

100

prescription_type:

Targeted (CDSA IV)

therapeutic_area:

BENZODIAZEPINES

leaflet_short:

Active ingredient group (AIG) number: 0111558001; AHFS:

authorization_status:

APPROVED

authorization_date:

2021-03-10

SPC

                                PRODUCT MONOGRAPH
CLONAPAM
®
Clonazepam Tablets, USP
0.5 mg. 1 mg, and 2 mg
ANTICONVULSANT
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION:
2150 St-Elzear Blvd. West
September 1, 2021
Laval, Quebec
H7L 4A8
Control #: 253836
_T/C_
_CLONAPAM_
_®_
_ Product Monograph Page 2 of 34_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
............................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
.....................................................................................
4
ADVERSE
REACTIONS.....................................................................................................12
DRUG INTERACTIONS
.....................................................................................................14
DOSAGE AND ADMINISTRATION
..................................................................................16
OVERDOSAGE
..................................................................................................................17
ACTION AND CLINICAL
PHARMACOLOGY..................................................................19
STORAGE AND STABILITY
.............................................................................................20
SPECIAL HANDLING INSTRUCTIONS
............................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................................21
PART II: SCIENTIFIC
INFORMATION...............................................................................
22
PHARMACEUTICAL INFORMATION
..............................................................................22
CLINICAL TRIALS
...................................................
                                
                                read_full_document
                                
                            

documents_in_other_languages

SPC SPC ֆրանսերեն 08-03-2021